DR. NEIL N SENZER, MD
Radiology at Worth St, Dallas, TX

2013026, Oct 10, 2013

Jun 13, 2013

13/917499

John J. Nemunaitis - Cedar Hill TX, US
Neil Senzer - Dallas TX, US
Bert W. O'Malley - Houston TX, US
David Lonard - Pearland TX, US

C12N 15/113, A61N 5/10, A61K 45/06, A61K 31/138, A61K 9/127, A61K 31/713

424450, 514 44 A, 4241301, 600 1

The present invention includes compositions and methods treating triple negative breast cancer comprising administering a therapeutically effective amount of a formulation that includes vector that expresses an SRC-1-specific bifunctional shRNA, an SRC-3-specific bifunctional shRNA, or both, to impair triple negative breast cancer cell growth.

2007024, Oct 25, 2007

Nov 17, 2006

11/601431

David Shanahan - Dallas TX, US
John Nemunaitis - Cedar Hill TX, US
Neil Senzer - Dallas TX, US
Phillip Maples - Pilot Point TX, US
Donald Rao - Dallas TX, US

A61K 48/00, A61K 31/7105, A61K 9/127, A61P 43/00, C12N 5/08, C12N 5/10

424450000, 435375000, 514044000

In certain preferred embodiments, the invention provides methods for treating cancer, which comprise (a) obtaining a specimen of cancer tissue from a patient; (b) obtaining a specimen of normal tissue in the proximity of the cancer tissue from such patient; (c) extracting total protein and RNA from the cancer tissue and normal tissue; (d) obtaining a protein expression profile of the cancer tissue and normal tissue using 2D DIGE and mass spectrometry; (e) identifying proteins that are expressed in such cancer tissue at significantly different levels than in the normal tissue; (f) obtaining a gene expression profile of the cancer tissue and normal tissue using microarray technology and comparing the results thereof to the protein expression profile; (g) prioritizing over-expressed proteins by assessing the connectivity thereof to other cancer-related or stimulatory proteins; (h) designing an appropriate RNA interference expression cassette to, directly or indirectly, modulate the expression of genes encoding such prioritized proteins; (i) incorporating said cassette into an appropriate delivery vehicle; and (j) providing the patient with an effective amount of the delivery vehicle to, directly or indirectly, modify the expression (i.e., production) of such proteins.

2009024, Oct 1, 2009

Mar 15, 2007

12/282618

Leo Linbeck, III - Houston TX, US
Martin Lindenberg - Bellaire TX, US
John J. Nemunaitis - Cedar Hill TX, US
Neil Senzer - Dallas TX, US
David Shanahan - Dallas TX, US

A61K 39/395, A61K 38/45, A61K 38/16, A61K 31/66, A61K 31/517

4241331, 424 945, 514 12, 514120, 5142664

A method of treating an individual comprising: evaluating the disease state of said individual through quantitative and/or qualitative assays; administering in amounts sufficient to treat said disease at least three agents wherein at least one agent is an inhibitor of the human epidermal receptor pathway, at least one agent is signal transduction inhibitor and at least one agent is an angiogenesis inhibitor and; reevaluating the disease state of said individual presenting through quantitative and/or qualitative assays. A composition comprising a first agent that is an inhibitor of the human epidermal receptor pathway, a second agent that is an angiogenesis inhibitor and a third agent that is an inhibitor of Akt wherein said first agent, second agent, third agent and combinations thereof are present in amounts that when administered to an individual in a diseased state are sufficient to treat said disease.

2011028, Nov 24, 2011

May 19, 2011

13/111677

Alex W. Tong - Dallas TX, US
Yu Yang - Allen TX, US
Donald Rao - Dallas TX, US
Phillip B. Maples - Pilot Point TX, US
Neil Senzer - Dallas TX, US
John J. Nemunaitis - Cedar Hill TX, US
Zhaohui Wang - Grapevine TX, US

GRADALIS, INC. - Carrollton TX

A61K 35/12, A61K 31/7105, A61K 31/7088, A61P 35/00, A61P 35/04

424 9321, 514 44 R, 514 44 A

Compositions and methods of augmenting the anti-tumor activities of docetaxel and other taxanes by combination with a bi-functional small hairpin RNA (bi-shRNA) is described herein. The instant invention describes the interactive outcome of STMN1 knockdown with docetaxel. In vitro docetaxel (DOC) dose response assessments with or without co-treatment with bi-shRNAin CCL-247 and SK-MEL-28 melanoma cells indicated that STMN1 knockdown significantly reduced DOC concentration needed to inhibit cancer cell growth by 50% (IC) of CCL-247 cells from 1.8±0.2 to 0.6±0.4 nm (n=3, p

2012025, Oct 4, 2012

Mar 1, 2012

13/410130

DONALD RAO - DALLAS TX, US
JOHN J. NEMUNAITIS - Cedar Hill TX, US
NEIL SENZER - DALLAS TX, US

GRADALIS, INC. - CARROLLTON TX

A61K 31/7105, C12N 15/85, A61P 35/00, C12N 15/63, C07H 21/02, A61K 9/127

424450, 536 245, 514 44 A, 4353201, 435455

The present invention includes bifunctional shRNAs capable of reducing an expression of a Stathmin 1 gene; wherein at least one target site sequence of the bifunctional RNA molecule is located within the Stathmin 1 gene, wherein the bifunctional RNA molecule is capable of activating a cleavage-dependent and a cleavage-independent RNA-induced silencing complex for reducing the expression level of Stathmin 1.

2013007, Mar 28, 2013

Sep 7, 2012

13/606476

John J. Nemunaitis - Cedar Hill TX, US
Neil Senzer - Dallas TX, US
Phillip B. Maples - Pilot Point TX, US
Donald Rao - Dallas TX, US

GRADALIS, INC. - Carrollton TX

A61K 31/7088

4242771

Compositions and methods for cancer treatment are discloses herein. More specifically the present invention describes an autologous cancer vaccine genetically modified for Furin knockdown and GM-CSF expression. The vaccine described herein attenuates the immunosuppressive activity of TGF-β through the use of bi-functional shRNAs to knock down the expression of furin in cancer cells, and to augment tumor antigen expression, presentation, and processing through expression of the GM-CSF transgene.

2013025, Oct 3, 2013

Mar 27, 2013

13/851464

John J. Nemunaitis - Cedar Hill TX, US
Neil Senzer - Dallas TX, US
Bert W. O'Malley - Houston TX, US
David Lonard - Pearland TX, US

BAYLOR COLLEGE OF MEDICINE - Houston TX
GRADALIS, INC. - Carrollton TX

A61K 31/713, A61K 45/06, C12N 15/113

424450, 514 44 R, 4241301, 4353201, 435375, 600 1

The present invention includes compositions and methods of making and using an expression vector comprising a promoter and a nucleic acid insert operably linked to the promoter, wherein the insert encodes one or more short hairpin RNAs (shRNA) capable of inhibiting an expression of a SRC-3 gene via RNA interference, wherein the one or more shRNA comprise a bifunctional RNA molecule that activates a cleavage-dependent and a cleavage-independent RNA-induced silencing complex for reducing the expression level of the SRC-3.

2013025, Oct 3, 2013

Apr 2, 2013

13/855109

Donald Rao - Dallas TX, US
Neil Senzer - Dallas TX, US

Gradalis, Inc. - Carrollton TX

C12N 15/113

424450, 4353201, 514 44 R, 435375

The present invention includes compositions and methods of making and using an imaging label comprising an expression vector comprising a promoter; and a nucleic acid insert operably linked to the promoter, wherein the insert encodes one or more short hairpin RNAs (shRNA) capable of inhibiting an expression of a target gene sequence that is a EWS-FLI1 fusion gene, a EWSR1-ERG fusion gene, or both in Ewing's sarcoma via RNA interference; wherein the one or more shRNA comprise a bifunctional RNA molecule that activates a cleavage-dependent and a cleavage-independent RNA-induced silencing complex for reducing the expression level of the target gene.